France Generic Injectables Market

ID: MRFR/LS/48942-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
France Generic Injectables Market Research Report: Size, Share, Trend Analysis By Formulation Type (Solution, Suspension, Emulsion, Lyophilized), By Route of Administration (Intravenous, Intramuscular, Subcutaneous, Intradermal), By Therapeutic Area (Oncology, Cardiovascular, Infectious Diseases, Hormonal Disorders) and By Packaging Type (Vials, Ampoules, Pre-filled Syringes, Bags) - Growth Outlook & Industry Forecast 2025 To 2035
France Generic Injectables Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)10.35%
2024 Market Size$ 976.05 Million
2025 Market Size$ 1,077.07 Million
2035 Market Size$ 2,883.19 Million
Key Players
Teva Pharmaceutical Industries Ltd
Sandoz International GmbH
Mylan N.V.
Fresenius Kabi AG
Baxter International Inc
Amgen Inc
Trends
  • Rising Demand for Cost-Effective Treatments
  • Regulatory Support for Market Expansion
  • Focus on Biosimilars and Complex Injectables
Opportunities
  • Increasing Healthcare Expenditure
  • Rising Focus on Preventive Healthcare
  • Technological Advancements in Manufacturing
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Formulation Type (USD Million)
      1. 4.1.1 Solution
      2. 4.1.2 Suspension
      3. 4.1.3 Emulsion
      4. 4.1.4 Lyophilized
    2. 4.2 Food, Beverages & Nutrition, BY Route of Administration (USD Million)
      1. 4.2.1 Intravenous
      2. 4.2.2 Intramuscular
      3. 4.2.3 Subcutaneous
      4. 4.2.4 Intradermal
    3. 4.3 Food, Beverages & Nutrition, BY Therapeutic Area (USD Million)
      1. 4.3.1 Oncology
      2. 4.3.2 Cardiovascular
      3. 4.3.3 Infectious Diseases
      4. 4.3.4 Hormonal Disorders
    4. 4.4 Food, Beverages & Nutrition, BY Packaging Type (USD Million)
      1. 4.4.1 Vials
      2. 4.4.2 Ampoules
      3. 4.4.3 Pre-filled Syringes
      4. 4.4.4 Bags
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sandoz International GmbH (AT)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Mylan N.V. (NL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Fresenius Kabi AG (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Baxter International Inc (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen Inc (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Hospira Inc (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Zydus Cadila (IN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Aurobindo Pharma (IN)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
    3. 6.3 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    4. 6.4 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
    5. 6.5 FRANCE MARKET ANALYSIS BY PACKAGING TYPE
    6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY FORMULATION TYPE, 2024 (% SHARE)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREA, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY PACKAGING TYPE, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY PACKAGING TYPE, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY FORMULATION TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      3. 7.2.3 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
      4. 7.2.4 BY PACKAGING TYPE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France Generic Injectables Market Segmentation

France Generic Injectables Market By Formulation Type (USD Million, 2025-2035)

  • Solution
  • Suspension
  • Emulsion
  • Lyophilized

France Generic Injectables Market By Route of Administration (USD Million, 2025-2035)

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Intradermal

France Generic Injectables Market By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Cardiovascular
  • Infectious Diseases
  • Hormonal Disorders

France Generic Injectables Market By Packaging Type (USD Million, 2025-2035)

  • Vials
  • Ampoules
  • Pre-filled Syringes
  • Bags

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.